References
1. Witzel M, Petersheim D, Fan Y, et al. Chromatin-remodeling factor
SMARCD2 regulates transcriptional networks controlling differentiation
of neutrophil granulocytes. Nat Genet. 2017;49(5):742-752.
2. Schim van der Loeff I, Sprenkeler EGG, Tool ATJ, et al. Defective
neutrophil development and specific granule deficiency caused by a
homozygous splice-site mutation in SMARCD2. J Allergy Clin
Immunol. 2021;147(6):2381-2385.e2382.
3. Yucel E, Karakus IS, Krolo A, et al. Novel Frameshift Autosomal
Recessive Loss-of-Function Mutation in SMARCD2 Encoding a Chromatin
Remodeling Factor Mediates Granulopoiesis. J Clin Immunol.2021;41(1):59-65.
4. Gombart AF, Shiohara M, Kwok SH, Agematsu K, Komiyama A, Koeffler HP.
Neutrophil-specific granule deficiency: homozygous recessive inheritance
of a frameshift mutation in the gene encoding transcription factor
CCAAT/enhancer binding protein–epsilon. Blood.2001;97(9):2561-2567.
5. Lee JW, Lee SE, Jung CW, et al. Romiplostim in patients with
refractory aplastic anaemia previously treated with immunosuppressive
therapy: a dose-finding and long-term treatment phase 2 trial.Lancet Haematol. 2019;6(11):e562-e572.
6. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer.Nat Rev Cancer. 2011;11(7):481-492.
7. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag Added to
Standard Immunosuppression for Aplastic Anemia. N Engl J Med.2017;376(16):1540-1550.
8. Xue Y, Ankala A, Wilcox WR, Hegde MR. Solving the molecular
diagnostic testing conundrum for Mendelian disorders in the era of
next-generation sequencing: single-gene, gene panel, or exome/genome
sequencing. Genet Med. 2015;17(6):444-451.
9. Boiocchi L, Orazi A, Ghanima W, Arabadjief M, Bussel JB, Geyer JT.
Thrombopoietin receptor agonist therapy in primary immune
thrombocytopenia is associated with bone marrow hypercellularity and
mild reticulin fibrosis but not other stromal abnormalities. Mod
Pathol. 2012;25(1):65-74.
10. Ghanima W, Geyer JT, Lee CS, et al. Bone marrow fibrosis in 66
patients with immune thrombocytopenia treated with
thrombopoietin-receptor agonists: a single-center, long-term follow-up.Haematologica. 2014;99(5):937-944.
11. Lekstrom-Himes JA, Dorman SE, Kopar P, Holland SM, Gallin JI.
Neutrophil-specific granule deficiency results from a novel mutation
with loss of function of the transcription factor CCAAT/enhancer binding
protein epsilon. J Exp Med. 1999;189(11):1847-1852.
12. Wada T, Akagi T, Muraoka M, et al. A Novel In-Frame Deletion in the
Leucine Zipper Domain of C/EBPε Leads to Neutrophil-Specific Granule
Deficiency. J Immunol. 2015;195(1):80-86.
13. Khanna-Gupta A, Sun H, Zibello T, et al. Growth factor
independence-1 (Gfi-1) plays a role in mediating specific granule
deficiency (SGD) in a patient lacking a gene-inactivating mutation in
the C/EBPepsilon gene. Blood. 2007;109(10):4181-4190.
14. Kimura S, Roberts AW, Metcalf D, Alexander WS. Hematopoietic stem
cell deficiencies in mice lacking c-Mpl, the receptor for
thrombopoietin. Proc Natl Acad Sci U S A. 1998;95(3):1195-1200.
15. Townsley DM, Desmond R, Dunbar CE, Young NS. Pathophysiology and
management of thrombocytopenia in bone marrow failure: possible clinical
applications of TPO receptor agonists in aplastic anemia and
myelodysplastic syndromes. Int J Hematol. 2013;98(1):48-55.
16. Lee JW, Lee SE, Jung CW, et al. Romiplostim in patients with
refractory aplastic anaemia previously treated with immunosuppressive
therapy: a dose-finding and long-term treatment phase 2 trial. The
Lancet Haematology. 2019.
17. Gill H, Wong RSM, Kwong Y-L. From chronic immune thrombocytopenia to
severe aplastic anemia: recent insights into the evolution of
eltrombopag. Ther Adv Hematol. 2017;8(5):159-174.
18. Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of
romiplostim in patients with lower-risk myelodysplastic syndrome and
thrombocytopenia. Journal of clinical oncology : official journal
of the American Society of Clinical Oncology. 2010;28(3):437-444.
19. Jong Wook L, HJ. J, L. S-E, WJ. C, Silvia P a, Il-Hoan O. Efficacy
and Safety of Romiplostim in Patients with Aplastic Anemia Refractory to
Immunosuppressive Therapy: 1-Year Interim Analysis of Phase 2 Clinical
Trial. . Blood cells, molecules & diseases. 2016;128:3910.
20. Metcalf D. Colony stimulating factors and hemopoiesis. Ann
Acad Med Singap. 1988;17(2):166-170.
21. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved
hematopoiesis in refractory aplastic anemia. N Engl J Med.2012;367(1):11-19.
Table 1: Review of literature about severe congenital neutropenia caused
by SMARCD2 mutations. The two siblings, the first mutation
produces three aberrant transcripts. All mutations resulted in
frameshifts and premature sequence termination.